UBS Downgrades Insmed (INSM) to Neutral; Arikayce Becomes a 2017 Story
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
US NTM Delayed Up to 12 Months; Cowen Cuts Price Target on Insmed (INSM) to $34
November 9, 2015 6:46 AM ESTCowen reiterated an Outperform rating on Insmed (NASDAQ: INSM), and cut the price target to $34.00 (from $38.00), folloiwng the company's 3Q15 earnings report. INSM reported Q3 EPS of ($0.50) vs consensus ($0.47). Cowen's lower price target on INSM is based on a potential 12 month delay... More
Insmed (INSM) Misses Q3 EPS by 3c
November 6, 2015 9:12 AM ESTInsmed (NASDAQ: INSM) reported Q3 EPS of ($0.50), $0.03 worse than the analyst estimate of ($0.47).
For earnings history and earnings-related data on Insmed (INSM) click here.
... More